ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11
Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.
Key findings
- The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
- Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
- Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
- PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
- For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveLimited evidenceTier 4 · clinicaln = 92
European journal of cancer (Oxford, England : 1990) · Mar 2013 · Phase II multicenter, single-arm neoadjuvant chemotherapy trial
TopotecanCisplatinsquamous cervical carcinomaadenosquamous cervical carcinomalocally-advanced cervical cancer (FIGO IB2, IIA, IIB) This phase II multicenter study enrolled 92 patients with locally advanced squamous or adenosquamous cervical cancer who received six weekly courses of topotecan (2 mg/m2) plus cisplatin (40 mg/m2) as neoadjuvant chemotherapy. The regimen was deliverable (96% completed six courses; 95% of courses given at full dose) and produced a clinical response rate of 77% and an overall pathologic response in 67% (optimal response 32%, downstaging 57%). Grade 3-4 hematologic toxicity occurred in 28% of patients, supportive therapies were given to 24%, and with median follow-up 18 months, 76% were alive and recurrence-free while 24% relapsed and 13% died.
Reported effects: treatment_completion 96%, n=92 · full_dose_course_percentage 95%, n=92 · +13 more
Studied with: cisplatin.
Key findings
- 96% of patients completed the six planned courses of chemotherapy.
- 95% of courses were administered at a full dose and without interruption or delay.
- Grade 3-4 haematological toxicity was observed in 28% of patients (5% out of cycles).
- Support therapies were given to 24% of patients.
- Clinical response rate was 77%.
- Overall pathologic response observed in 67% of patients.
- Optimal pathologic response rate was 32%.
- Disease downstage occurred in 57% of patients.
- Nodal metastases occurred in 36% of patients.
- Adjuvant radiotherapy and/or chemotherapy was prescribed in 55% of patients.
- Median follow-up was 18 months; 76% alive and free from recurrence, 24% relapsed, 13% died.
Limitations: Single-arm Phase II design with no randomized or concurrent control group; Relatively short median follow-up (18 months) for survival outcomes; Adjuvant therapy was given to 55% of patients, which may confound interpretation of longer-term outcomes; Sample size (n=92) limits precision of survival and subgroup estimates; Endpoints are primarily response and short-term outcomes rather than long-term randomized efficacy.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed